tetano
Editor, Senior Moderator
J Med Virol
. 2021 Dec 22.
doi: 10.1002/jmv.27542. Online ahead of print.
Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis
Huai-Rong Xiang[SUP] 1 [/SUP], Bei He[SUP] 1 [/SUP], Yun Li[SUP] 1 [/SUP], Xuan Cheng[SUP] 1 [/SUP], Qi-Zhi Zhang[SUP] 1 [/SUP], Wen-Xing Peng[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19.
Methods: We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19.
Results: Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome.
Conclusion: Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease. Combinations of bamlanivimab and etesevimab has a significant relative risk reduction (RRR) for COVID-related hospitalization or death for patients than monotherapy 700mg group. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab or plus etesevimab are warranted in the future. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Immunotherapy; bamlanivimab.
. 2021 Dec 22.
doi: 10.1002/jmv.27542. Online ahead of print.
Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis
Huai-Rong Xiang[SUP] 1 [/SUP], Bei He[SUP] 1 [/SUP], Yun Li[SUP] 1 [/SUP], Xuan Cheng[SUP] 1 [/SUP], Qi-Zhi Zhang[SUP] 1 [/SUP], Wen-Xing Peng[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34936121
- DOI: 10.1002/jmv.27542
Abstract
Background: Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19.
Methods: We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19.
Results: Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome.
Conclusion: Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease. Combinations of bamlanivimab and etesevimab has a significant relative risk reduction (RRR) for COVID-related hospitalization or death for patients than monotherapy 700mg group. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab or plus etesevimab are warranted in the future. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Immunotherapy; bamlanivimab.
